marijuana stock news

Canna-Pet(TM) Happy New Year Sale

Take 20% Off All Orders Over $75 Until January 3rd

OULDER, CO–(Marketwired – Dec 24, 2014) –Canna-Pet™ celebrates the New Year with 20% off all orders over $75! Canna-Pet™, the leading innovator of over-the-counter cannabinoid products for animals, announces the launch of its “Happy New Year Sale.” Sale starts today and runs until midnight on January 3.

Buy any combination of top-selling Canna-Pet™ CBD capsules for dogs and cats, or try our new Canna-Biscuit dog treats in 5 exciting flavors. Simply spend a minimum of $75 to get 20% off your entire order up to a maximum of $300 per order. Place an order now at

During this festive season Canna-Pet™ products are particularly popular for anxious pets, as evidenced by many consumers who have reported calmer behavior especially during thunderstorms, fireworks and travel. All products are “Made in the USA,” with 100% natural, non-GMO hemp, and are held to the same food quality standards as the products you’d serve to your own family. Canna-Pet™ products are an ideal way to learn about the health benefits of hemp-based cannabinoids.

About Canna-Pet™ Products for Pet Health
Canna-Pet™ is the culmination of years of research and development to provide the benefits of CBD and hemp without the “high” typically associated with THC. Today, Canna-Pet™ offers the leading veterinarian recommended, over-the-counter CBD products for cats, dogs and other domesticated animals. The company uses non-GMO hemp as starting material and all products are proudly made in the USA. In addition to CBD, Canna-Pet products contain proprietary ratios of other cannabinoids and terpenes, which make the products uniquely effective. Canna-Pet™ is the leading producer of safe, hemp-based, cannabinoid (CBD) containing products, which are available under an exclusive commercial license agreement with Cannabis Therapy Corp. (OTCQB: CTCO). Order online at: and join us on Facebook and Twitter.

For veterinary inquiries visit:

FDA Disclosure: The statements in this news release have not been evaluated by the Food and Drug Administration (FDA). The products and statements mentioned in this release are not intended for humans, or to diagnose, treat, cure, or prevent any disease.

For additional information, please contact:
Canna-Pet™ Support

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 |
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Organigram Holdings Inc. (OGI) to Report Second Quarter 2022 Results on April 12, 2022

Organigram to Report Second Quarter 2022 Results on April 12, 2022 Organigram…

$PMCB Cancer Treatments

FDA’s Record Approvals Bode Well for PharmaCyte’s Cancer Treatments BALTIMORE, Apr. 7,…

$CARA Announces Successful Completion of Phase 1b Trial

Cara Therapeutics Reports Positive Top-Line Data From Phase 1b Trial of I.V.…